Myo-inositol supplement during pregnancy in women with type 2 diabetes
Tests myo-inositol with folic acid in pregnant women with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Antenatal Myo-inositol Supplementation in Pre-existing Diabetes
Key facts
- Where
- Singapore, SingaporeSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 45 years old?
Source: NCT07241221, who can take part
Where in Singapore
- National University HospitalSingapore, SingaporeTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National University Hospital, Singapore
- Trial code
- NCT07241221
- Record updated
- 9 December 2025
- Original description
This feasibility pilot study aims to gather data that can guide the design of a larger, more comprehensive trial to establish the effects of myo-inositol supplementation on supporting healthy outcomes in pregnancies complicated by Type 2 Diabetes Mellitus (T2DM). It seeks to assess myo-inositol's potential to support fetal and neonatal health, and optimise maternity outcomes as a complementary approach and adjuvant to existing diabetes mellitus therapies, as well as investigate the underlying biological mechanisms.Read full original descriptionShow less
Antenatal Myo-inositol Supplementation in Pre-existing Diabetes to Promote Normal Neonatal Outcomes
This feasibility pilot study aims to gather data that can guide the design of a larger, more comprehensive trial to establish the effects of myo-inositol supplementation on supporting healthy outcomes in pregnancies complicated by Type 2 Diabetes Mellitus (T2DM). It seeks to assess myo-inositol's potential to support fetal and neonatal health, and optimise maternity outcomes as a complementary approach and adjuvant to existing diabetes mellitus therapies, as well as investigate the underlying biological mechanisms.
Inclusion: Pregnant women aged 21 years to 45 years old at the time of recruitment; Ongoing, viable, singleton intrauterine pregnancy; Between 12+0 days-16+6 days weeks' gestation at recruitment; T2DM diagnosed by a documented 75g Oral Glucose Tolerance Test (OGTT) showing a fasting glucose of >7 mmol/L or 2h glucose >11.1 mmol/L, or an HbA1C >6.5%, either prior to pregnancy or during the first 16 weeks of the index pregnancy; Intend to receive antenatal care and give birth at NUH; Willing to provide written, informed consent; Able to swallow capsules and comply with trial procedures.
Exclusion: Severe allergy to food items requiring carriage of an Epipen at all times; Known or suspected fetal aneuploidy or genetic/structural anomaly.